Empowering AI-driven drug discovery with experimental validation
Artificial Intelligence (AI) is transforming the landscape of drug discovery. At Axxam, we help biotech and pharma companies translate their AI-driven computational predictions into validated biological results. We deliver the high-quality experimental data required to train, refine, and validate AI-predictive models accelerating the pipeline of AI-based drug discovery.
From target and pathway validation to assay development and hit-to-lead optimization, Axxam offers a seamless path from in silico discovery to experimental proof. We understand the unique challenges Artificial Intelligence-based companies face and we provide the tools and know-how to timely meet them.
Whether you are identifying novel targets, uncovering new pathways, or designing potential bioactive compounds, Axxam is your ideal partner for bridging computation and wet biology.
Target & pathway validation
At Axxam, we specialize in the development of advanced biological in-vitro assays that can rigorously test the predictions generated by AI platforms. We offer a full suite of molecular biology technologies to validate targets and pathways, including:
- Gene expression profiling using TaqManTM technology
- Inducible knock-out cell lines for disease modeling
- RNA interference approach (including siRNA & shRNA based screening)
- Overexpression studies
In addition, our high-resolution phenotypic platform allows us a parallel evaluation of molecular and cellular changes in the complex physiological environment of the cells.
Compound validation
Axxam’s expertise in compound validation allows AI-generated molecules to be tested in a variety of highly informative in-vitro assays. We conduct potency and efficacy assessments using a combination of primary, specificity, selectivity and orthogonal assays, alongside mechanism-of-action (MoA) studies such as time-dependent inhibition, competitive vs not competitive MoA, wash-out experiments, jump dilution experiments, residence time, covalent inhibitor characterization (Kinact/KI), etc.
Our platforms support a wide range of readouts, including fluorescence, luminescence, absorbance, and advanced electrophysiological techniques — including nuclear, lysosomal, and mitochondrial patch-clamp recordings. This enables comprehensive evaluation of compound behavior across diverse biological systems.
Highlight – Integrated assay development for compound validation
For AI-based companies exploring novel mechanisms or unconventional targets, Axxam offers custom assay development services tailored to your specific needs. We create both cell-based and cell-free assays for all major target classes — from GPCRs and ion channels to transporters and protein-protein interactions.
Cell-free functional and binding assays
- Homomultimeric and heteromultimeric targets
- Integral transmembrane enzymes
- Protein-protein / protein-DNA / protein-RNA / protein-probe (PROTAC) interactions
- Protein degradation assays
- TRIC / DSF / TSA
Cell-based functional and phenotypic assays
- All target classes (GPCRs, ion channels, solute carriers, etc.)
- Stable or transient (inducible/constitutive) expression
- Different cellular backgrounds including iPSC-derived cells
- Know-how for relevant biological processes
(e.g., autophagy, lysosomal storage diseases, mitophagy, phagocytosis, protein degradation & aggregation)
In addition, our suite of ready-to-use assays is immediately available for compound testing. These include over 150 functional cell-based / cell-free assays and a growing collection of phenotypic assays addressing key biological processes such as autophagy, mitophagy, and protein aggregation.
Hit-to-lead and lead optimization
Through our integrated hit-to-lead and lead optimization services, Axxam enables the seamless progression of validated hits into optimized lead compounds, including:
- Design & synthesis of compounds / selection of analogues (hit expansion)
- Regular compound test (DRC) and MoA studies
- In-vitro ADME
- Cardiac safety panel & off-target panel
- Disease relevant models
- In-vivo DMPK profiling
- Structural analysis
- Compound management (library storage and reformatting)
and data science - Medicinal chemistry consultancy
- Data management solutions – integrated database generation and maintenance
(CDD Vault)
Our fully integrated biology and chemistry teams work hand in hand, eliminating inefficiencies, reducing risks, and accelerating timelines. For AI-driven companies, this means less time spent managing multiple vendors and more time focused on innovation.